A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial
Citation:
McEvoy N.L, Clarke J.L, Mc Elvaney O.J, Mc Elvaney O.F, Boland F, Hyland D, Geoghegan P, Donnelly K, Friel O, Cullen A, Collins A.M, Fraughen D, Martin-Loeches I, Hennessy M, Laffey J.G, Mc Elvaney N.G, Curley G.F, A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial, Trials, 22, 1, 2021Download Item:
Abstract:
The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in
Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous
Prolastin®(plasma-purified alpha-1 antitrypsin) reduces circulating plasma levels of interleukin-6 (IL-6). Secondary
objectives are to determine the effects of intravenous Prolastin® on important clinical outcomes including the
incidence of adverse events (AEs) and serious adverse events (SAEs).
Author's Homepage:
http://people.tcd.ie/mhennessDescription:
PUBLISHED
Author: Hennessy, Martina
Type of material:
Journal ArticleCollections
Series/Report no:
Trials;22;
1;
Availability:
Full text availableDOI:
http://dx.doi.org/10.1186/s13063-021-05254-0Metadata
Show full item recordLicences: